Anne Nikkonen

Quantitative insights into effects of intrapartum antibiotics and birth mode on infant gut microbiota in relation to well-being during the first year of life

K. Korpela, A. Salonen, A. Nikkonen, 2021, medRxiv.

Infliximab and its biosimilar produced similar first‐year therapy outcomes in patients with inflammatory bowel disease

K. Kolho, Anne Nikkonen, 2020, Acta paediatrica.

Quantitative Fecal Microbiota Profiles Relate to Therapy Response During Induction With Tumor Necrosis Factor α Antagonist Infliximab in Pediatric Inflammatory Bowel Disease

K. Korpela, A. Salonen, Miikka Höyhtyä, 2022, Inflammatory bowel diseases.

The gut fungal and bacterial microbiota in pediatric patients with inflammatory bowel disease introduced to treatment with anti-tumor necrosis factor-α

K. Korpela, A. Salonen, R. Ventin-Holmberg, 2022, Scientific Reports.

Therapy outcome related to adalimumab trough levels in pediatric patients with inflammatory bowel disease

K. Kolho, P. Hiltunen, L. Merras-Salmio, 2021, Scandinavian journal of gastroenterology.

Antibiotics in early life associate with specific gut microbiota signatures in a prospective longitudinal infant cohort

K. Korpela, A. Salonen, K. Kolho, 2020, Pediatric Research.

The Effect of Antibiotics on the Infant Gut Fungal Microbiota

K. Korpela, A. Salonen, R. Ventin-Holmberg, 2022, Journal of fungi.

Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting

K. Kolho, L. Merras-Salmio, Anne Nikkonen, 2023, European journal of pediatrics.